A Therapeutic Antibody for Cancer, Derived from Single Human B Cells
Some patients with cancer never develop metastasis, and their host response might provide cues for innovative treatment strategies. We previously reported an association between autoantibodies against complement factor H (CFH) and early-stage lung cancer. CFH prevents complement-mediated cytotoxicity (CDC) by inhibiting formation of cell-lytic membrane attack complexes on self-surfaces. In an effort to translate these findings into a biologic therapy for cancer, we isolated and expressed DNA sequences encoding high-affinity human CFH antibodies directly from single, sorted B cells obtained from patients with the antibody. The co-crystal structure of a CFH antibody-target complex shows a conformational change in the target relative to the native structure. This recombinant CFH antibody causes complement activation and release of anaphylatoxins, promotes CDC of tumor cell lines, and inhibits tumor growth in vivo. The isolation of anti-tumor antibodies derived from single human B cells represents an alternative paradigm in antibody drug discovery.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC), Basic Energy Sciences (BES); LUNGevity Foundation, the Dept. of Defense; National Institutes of Health (NIH)
- Grant/Contract Number:
- W-31-109-Eng-38; W81XWH-13-1-0189; UL1TR001117
- OSTI ID:
- 1325319
- Alternate ID(s):
- OSTI ID: 1256369
- Journal Information:
- Cell Reports, Journal Name: Cell Reports Vol. 15 Journal Issue: 7; ISSN 2211-1247
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- Netherlands
- Language:
- English
Web of Science
Similar Records
Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori)
Regulation of IL-2 induced proliferation and cytotoxicity in human natural killer cells by monoclonal antibodies